StreetInsider.com News Articles

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

Cervical spinal cord stimulation can immediately improve arm movement after stroke. A University of Pittsburgh study supported by MindMaze Therapeutics' technology tests whether pairing stimulation with intensive therapy can make those gains last.

GENEVA, July 9, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable, precision neurotherapeutics, today announced that its technology is being used in a University of Pittsburgh study evaluating a combination approach to post-stroke arm recovery, pairing cervical epidural spinal cord

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Thu, 09 Jul 2026 01:35:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

GENEVA, Switzerland, July 1, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that the SwissNeuroRehab consortium has enrolled the first patients in a High-Dose, High-Intensity (HDHI) neurorehabilitation study. In parallel, MindMaze Therapeutics has launched the REACT-AVC study at Hospices Civils de Lyon, focused on early outpatient and home-based stroke rehabilitation. This progress marks a pivotal milestone in the Company's strategy to consolidate its footprint in key European markets by obtaining

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Wed, 01 Jul 2026 01:22:00 -0400

MindMaze Therapeutics Announces Results of Annual General Meeting

Thu, 25 Jun 2026 07:14:00 -0400

GENEVA, June 25, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced the results of its Annual General Meeting held earlier today.

Shareholders approved all proposals submitted by the Board of Directors, except the proposed increase in conditional share capital, which did not obtain the required qualified majority.

Shareholders re-elected Walid Hanna, Olaf Blanke and Martin Reiss to the Board of Directors and elected Brad Hollinger, Founder, Chairman and Chief Executive Officer of